r
SCIENTIFIC ADVISORY BOARD
DR. BRAD THOMPSON, PHD
Chairman of the Cellasrra SAB, CTO
Dr. Thompson, Ph.D., Chairman & CEO of Wyvern Pharmaceuticals, and CEO & Co-Founder of Kickshaw Ventures, is an experienced and highly respected biotechnology professional for more than 40 years.He is also an inventor of several patents granted or pending in the viral/ gene therapy area and of the proprietary technology platform assigned to Cellastra. He served for many years as Director and the Chairman of BIOTECanada, and as Executive Chairman, CEO and President of Oncolytic Biotech Inc. He started his career in biotech as Head of Biotechnology at The Alberta Research Council where he was responsible for GMP manufacturing for biologics as well held a variety of other positions. He served, amongst others, as a Director of Signal Gene, Paladin Labs Inc., Transition Therapeutics and Immunovaccine, Inc., and is a current board member of He is a current Direcor Erad Therapeutics Inc.. Dr Thompson is also a member of the Advisory Board of Lifeboat Foundation Biosciences Inc.He received a B.Sc. from the University of Alberta and a Ph.D. in microbiology and immunology from the University of Western Ontario.
DR. FOLKE SJOBERG, MD, PHD
Sr. Scientific Advisor, Tissue Repair, Burn Injuries
PRofessor Sjoberg is a world-renowned, leading expert in the field of burn care/wound healing/tissue repair. He is Professor of Burn Surgery/Critical Care, Department of Clinical and Experimental Medicine (IKE), Linköping University and the Burn Center, Depts. of Hand, Plastic Surgery and Intensive Care, Linköping University Hospital, Linköping, Sweden. Since 2005 he is member Executive Committee of International Society For Burn Injuries and Program Chair since 2011. From 2007 to 2009 he served as President of the European Burns Association and since 2011 he is a board member of the Verification Committee, American Burn Association. He is coauthor of more than 200 peer reviewed publications, eight books. He has supervised 40 PhD students, about 20 dissertations, and served as primary investigator of 150 clinical trials Phase 1-4. He received his MD in 1983, and PhD in 1990, both from Linkoping University. He is a prolific lecturer at conferences around the world, and serves on the editorial board of seven International Journals
DR. HRISTOPHER EVANS, PHD
Scientific Advisor, Gene Therapy, Tissue Repair
Professor Evans is a leading expert in the field of tissue repair and new treatment modalities, including gene therapy in arthritis. He is currently Director of the Rehabilitation Medicine Research Center, Mayo Clinic, Rochester, and Professor of Orthopedics, Physical Medicine and Rehabilitation. He previously served as Director of Center for Advanced Orthopedic Studies, Beth Israel Deaconess Medical Center, Harvard Medical School. and is Maurice Müller Professor of Orthopaedic Surgery Emeritus, Harvard Medical School. Originally from Great Britain, Dr. Evans holds a bachelor's degree in genetics and microbiology, a Ph.D. in biochemistry from the University of Wales, a master's degree in history and philosophy of science from the University of Pittsburgh, and a D.Sc. from the University of Wales. He is the author of more than 300 peer reviewed scientific publications. He served as President Orthopedic Research Society 2004 -2005, and has served as the Chair, Scientific Advisory Board, Journal of Orthopedic Research . In 2009 he won the Marshall R Urist MD Award, Orthopedic Research Society for excellence in tissue regeneration, and in 2010 the Arthur Steidler MD Award, Orthopedic Research Society for understanding of the musculoskeletal system. In 2016 he was elected an inaugural Fellow of International Orthopaedic Research (FIOR)
DR. MAGDA FPRSBERG, PHD
Scientific Adviser, Orthopedic & Medical devices
Dr Forsberg obtained her Ph.D. in animal development and epigenetics from Uppsala University in Sweden, and did a Postdoctoral Fellowship in Reprogramming and Neurobiology at the Karolinska Institutet in Sweden, and is the author of publications exploring fundamental aspects of cell biology. Dr. Forsberg, who became an Assistant Professor at the Karolinska Institute, Stockholm, has worked in the development of cell replacement therapy for neuro-degenerative diseases, focusing on stem cell biology, cell differentiation and clinical applications. Dr. Forsberg is currently President & CEO of DVL-op MEDICO Inc, based in Valencia, CA, involved in the production and commercialization orthopedic and medical devices.
